Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results

Acta Myologica

Volumn 22, Issue MAY, 2003, Pages 15-21

  Politano, Luisa ^b   Nigro, G ^c   Nigro, V ^a   Pilus, G ^c   Papparella, S ^c   Paciello, O ^c   Comi, L I ^c  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b Policlinico   (Italy)

^c NONE

Author keywords

Aminoglycosides; Duchenne dystrophy; Dystrophin recovery; Gentamicin

Indexed keywords

DYSTROPHIN; GENTAMICIN;

ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; CLINICAL PROTOCOL; DENSITOMETRY; DRUG DOSE REGIMEN; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MONITORING; MUSCLE BIOPSY; NEPHROTOXICITY; NONSENSE MUTATION; OTOTOXICITY; POINT MUTATION; PROTEIN EXPRESSION; SKELETAL MUSCLE; STOP CODON; VITAL CAPACITY; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CODON, NONSENSE; DRUG ADMINISTRATION SCHEDULE; DYSTROPHIN; FOLLOW-UP STUDIES; GENTAMICINS; HUMANS; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0043092426     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Nigro V, Politano L, Nigro G, et al. Detection of a nonsense mutation in the dystrophin gene by multiple SSCP. Hum Molec Genet 1992;1:517-20.
2. Nigro V, Nigro G, Comi LI, et al. Novel small mutations along the DMD/ BMD gene associated with different phenotypes. Hum Molec Genet 1994;3:1907-8.
3. Barton-Davis E, Cordier L, Shoturma DI, et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-81.
4. Palmer E, Whilhem JM, Sherman F. Phenotypic suppression of nonsense mutants in yeasts by aminoglycoside antibiotics. Nature 1979;277:148-50
5. Schroeder R, Waldsich C, Wank H. Modulation of RNA function by aminoglycoside antibiotics. The EMBO Journal 2000;19:1-9.
6. Howard MT, Shirts BH, Perros LM, et al. Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 2000;48:164-9.
7. Nigro G, Comi LI, Limongelli FM, et al. Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle & Nerve 1983;6:253-62.
8. Nicholson LVB, Davison K, Falkous G, et al. Dystrophin in skeletal muscle: I. Western blot analysis using a monoclonal antibody. J Neurol Sci 1989;94:125-36.
9. Swan SK, Aminoglycoside nephrotoxicity. Semin Nephrol 1997;17:27-33
10. Morris HT. Antibiotic therapeutics in laboratory animals. Lab Anim 1995;29:16-36.
11. Hauser MA, Amalfitano A, Kumar-Singh R, et al. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromusc Disord 1997;4:1251-8.
12. Senior K. Duchenne muscular dystrophy improved by gentamicin (news). Mol Med Today 1999;5:461.
13. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995;4:1251-8.
14. Bass KD, Larkin SE, Paap C, et al. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 1998;33:1104-7.
15. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001;49:706-11.